+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

E

Actively Recruiting

This research aims to test a new systematic screening program designed to detect early risk of type 2 diabetes mellitus T2DM and cardiovascular diseases CVDs in individuals aged 50 years living in the Ascoli Piceno province without prior diagnosis. The study uses CUORE and FINDRISC tools developed specifically for this project to assess 10-year risks. The screening will take place throughout 2026 at the Prevention Department locations in Ascoli Piceno and San Benedetto del Tronto within the Local Health Authority. The intervention involves inviting eligible individuals via letter to participate in the screening. Participants will book appointments through a regional system and attend the Prevention Department where healthcare professionals will explain the study, obtain consent, and collect questionnaire and sociodemographic data. Clinical parameters such as anthropometric measures, blood pressure, cholesterol, and HbA1c for higher risk FINDRISC scores will be collected using small medical devices and finger-prick tests. Based on risk scores, tailored prevention pathways will be suggested, and results may be added to participants electronic health records with consent. Participants will be followed up with phone calls at 3 and 6 months after screening to assess adherence to suggested pathways like visits to general practitioners or lifestyle counseling. Data collection will include clinical, questionnaire, and sociodemographic information. The main outcome is to evaluate screening adherence by coverage at the end of 2026, along with assessment of 10-year risk scores, risk detection rates, pathway adherence, and results according to participant characteristics.

Age: 50Years - 50YearsAll Genders
2 locations
S

Actively Recruiting

Researchers are investigating ischemic stroke cases in patients who are on oral anticoagulants due to atrial fibrillation or other cardioembolic arrhythmias. This observational study, called ASPERA, aims to understand the characteristics of these stroke cases and to evaluate the short- and long-term outcomes of different strategies used to prevent recurrent strokes. The study includes both retrospective and prospective data collection from multiple centers worldwide, coordinated by the University of LAquila. The study has two parts ASPERA-R and ASPERA-P. ASPERA-R collects retrospective data over five years, focusing on baseline demographic, clinical, and neuroimaging features of ischemic strokes in patients on oral anticoagulants. ASPERA-P enrolls patients prospectively for two years with follow-up for five years to assess risks of stroke recurrence and safety events under different secondary prevention approaches, such as continuing or changing oral anticoagulation. Participants will have their data collected at several time points, including hospital admission, discharge, and follow-ups at 90 days, 1 year, and 5 years after stroke. Assessments include clinical evaluations, neuroimaging exams, and monitoring for stroke recurrence, bleeding events, heart attacks, and mortality. The study tracks outcomes to better understand risks and to identify features linked to stroke recurrence and safety events, with total participation lasting up to seven years for prospective patients.

Age: 18Years +All Genders
47 locations
E

Actively Recruiting

This research aims to enhance self-management skills for adults with Type 2 Diabetes Mellitus T2DM living in the Marche region of Italy. It evaluates a mobile health m-health solution personalized by diabetologists and integrated with electronic patient records, comparing its use to usual diabetes care. The main goal is to measure changes in glycated haemoglobin HbA1c levels over a 12-month period to assess the effectiveness of this digital support. Participants will be randomly assigned to either a treated group using the m-health solution or a control group receiving regular care. The m-health system includes mobile apps for tracking health data such as blood sugar, physical activity, and diet, sending alerts and motivational messages, allowing communication with healthcare professionals, and providing access to educational materials. Healthcare providers will monitor patient data through an integrated electronic platform. The treatment lasts 12 months with evaluations at baseline, 4, 8, and 12 months. During the study, participants will engage in clinical assessments and complete validated questionnaires covering disease severity, medication adherence, lifestyle habits, self-efficacy, and quality of life. Data will be collected from self-reports, clinical visits, and the m-health app. Researchers will also explore patients experience and satisfaction with the m-health solution and assess its cost-effectiveness. No extra visits or lab tests beyond routine care are required.

Age: 18Years +All GendersPhase Not Applicable
11 locations
S

Actively Recruiting

This research aims to compare the effects of a new low glucose peritoneal dialysis solution called XyloCore against standard glucose-based solutions in patients with End-Stage Renal Disease ESRD who are undergoing Continuous Ambulatory Peritoneal Dialysis CAPD. The study is randomized, controlled, and open-label with blinded assessment of the main outcomes, conducted over a 6-month period. It includes patients already using common glucose peritoneal dialysis solutions and Extraneal for their long-dwell exchange. Participants will be randomly assigned to receive either the experimental XyloCore solution or continue with their current glucose peritoneal dialysis solutions. XyloCore is provided in low, medium, or high strengths matched to the glucose concentration of the patients prior prescription, while the control group maintains their usual glucose-based solutions. Both groups will continue using Extraneal for the nocturnal long-dwell exchange. Dialysis prescriptions may be adjusted by investigators to meet a target dialysis adequacy measure KtV > 1.7 per week. Throughout the study, participants will undergo regular assessments including measurement of dialysis adequacy total weekly KtVurea, blood tests such as HbA1c, cholesterol levels, hemoglobin, and insulin, as well as monitoring of kidney function, fluid removal, fatigue, and adverse events. The study includes follow-up visits for up to 6 months, with careful monitoring of safety and treatment effects. The trial is sponsored by Iperboreal Pharma Srl and uses centralized randomization with blinded evaluation of primary endpoints.

Age: 18Years +All GendersPhase 3
41 locations
E

Actively Recruiting

Researchers are studying mild traumatic brain injury TBI, a common reason for emergency department visits. The study focuses on how brain computed tomography CT scans are used to detect brain injuries in patients with mild TBI. It aims to analyze the variability of CT scan use across Italian emergency departments, evaluate existing scoring systems that guide CT use, and develop a new model to better predict patient outcomes after mild head trauma. The study observes adult patients with mild TBI who present to emergency departments. Researchers will collect data on CT scan use and assess the accuracy of current clinical decision tools like the Canadian CT Head Rule and NICE guidelines. They will then work to create an improved scoring system to help doctors decide when CT scans are necessary, aiming to reduce unnecessary radiation exposure and healthcare costs. Participants will be monitored from September 2025 through August 2027 with data collected on CT scan usage and patient outcomes. The study will validate existing scores between September 2026 and August 2027 and develop a new predictive score by August 2027. Researchers will review patient data, including Glasgow Coma Scale scores, to measure how well the new tool predicts clinically relevant events. The total study duration spans from January 2026 to August 2027.

Age: 18Years +All Genders
59 locations
Z

Actively Recruiting

Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.

Age: 18Years +All GendersPhase 3
1190 locations